Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.
The targeted therapies available to treat metastatic kidney cancer include vascular endothelial growth factor (VEGF) inhibitors, bevacizumab, sorafenib, sunitinib, pazopanib, and the mTor inhibitors temsirolimus and everolimus. These agents have significantly improved patient outcomes but are associated with toxicities. The most common toxicities seen with the VEGF inhibitors are hypertension, fatigue, and hand- foot syndrome. The mTor inhibitors exhibit a different toxicity profile which includes hyperglycemia and hypertriglyceridemia. Recognition and understanding the mechanism of the toxicities is crucial for optimal patient management.
Written by:
Patel P, Srinivas S. Are you the author?
Reference: Curr Clin Pharmacol. 2011 Aug 1;6(3):181-8.
PubMed Abstract
PMID: 21827392
UroToday.com Renal Cancer Section
